The review found no eligible studies for this question.
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
Probiotics may leads to higher clinical remission compared with placebo (low certainty).
Probiotics showed no clear difference in clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether LMWH + standard therapy changes clinical remission compared with standard therapy (very low certainty).
It is very uncertain whether inulin and oligofructose 15 g changes clinical remission (9 weeks) compared with inulin and oligofructose 7.5 g daily (very low certainty).
Cannabidiol showed no clear difference in clinical remission at 10 weeks compared with placebo (low certainty).
Budesonide probably leads to lower clinical remission (ITT analysis) compared with mesalamine (moderate certainty).
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
It is very uncertain whether probiotics changes maintenance of clinical remission (52 weeks) compared with placebo (very low certainty).
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).
Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with comparator 5‐ASA (moderate certainty).
Oral 5‐ASA showed no clear difference in failure to induce global or clinical remission compared with SASP (moderate certainty).
Etrolizumab probably leads to lower failure to enter clinical remission at week 10 compared with placebo (moderate certainty).
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).